TY - JOUR
T1 - Chronic Constipation
AU - Bharucha, Adil E.
AU - Wald, Arnold
N1 - Funding Information:
Grant Support: This study was supported in part by grant R01 DK78924 from the National Institutes of Health.
Publisher Copyright:
© 2019 Mayo Foundation for Medical Education and Research
PY - 2019/11
Y1 - 2019/11
N2 - Constipation is a common symptom that may be primary (idiopathic or functional) or associated with a number of disorders or medications. Although most constipation is self-managed by patients, 22% seek health care, mostly to primary care physicians (>50%) and gastroenterologists (14%), resulting in large expenditures for diagnostic testing and treatments. There is strong evidence that stimulant and osmotic laxatives, intestinal secretagogues, and peripherally restricted μ-opiate antagonists are effective and safe; the lattermost drugs are a major advance for managing opioid-induced constipation. Constipation that is refractory to available laxatives should be evaluated for defecatory disorders and slow-transit constipation using studies of anorectal function and colonic transit. Defecatory disorders are often responsive to biofeedback therapies, whereas slow-transit constipation may require surgical intervention in selected patients. Both efficacy and cost should guide the choice of treatment for functional constipation and opiate-induced constipation. Currently, no studies have compared inexpensive laxatives with newer drugs that work by other mechanisms.
AB - Constipation is a common symptom that may be primary (idiopathic or functional) or associated with a number of disorders or medications. Although most constipation is self-managed by patients, 22% seek health care, mostly to primary care physicians (>50%) and gastroenterologists (14%), resulting in large expenditures for diagnostic testing and treatments. There is strong evidence that stimulant and osmotic laxatives, intestinal secretagogues, and peripherally restricted μ-opiate antagonists are effective and safe; the lattermost drugs are a major advance for managing opioid-induced constipation. Constipation that is refractory to available laxatives should be evaluated for defecatory disorders and slow-transit constipation using studies of anorectal function and colonic transit. Defecatory disorders are often responsive to biofeedback therapies, whereas slow-transit constipation may require surgical intervention in selected patients. Both efficacy and cost should guide the choice of treatment for functional constipation and opiate-induced constipation. Currently, no studies have compared inexpensive laxatives with newer drugs that work by other mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=85074139881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074139881&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2019.01.031
DO - 10.1016/j.mayocp.2019.01.031
M3 - Review article
C2 - 31054770
AN - SCOPUS:85074139881
SN - 0025-6196
VL - 94
SP - 2340
EP - 2357
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 11
ER -